Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. by Lai, C. L. et al.
Br. J. Cancer (1989), 60, 928-933
© The Macmillan Press Ltd., 1989
Recombinant a2 interferon is superior to doxorubin for inoperable
hepatocellular carcinoma: a prospective randomised trial
C.-L. Lail, P.-C. Wu2, A.S.-F. Lok', H.-J. Lin3, H. Ngan4, J.Y.-N. Lau', H.-T. Chung',
M.M.-T. Ng', E.-K. Yeoh5 & M. Arnold6
'Department ofMedicine, 2Department ofPathology, 3Clinical Biochemistry Unit and 4Department ofDiagnostic Radiology,
University ofHong Kong, Queen Mary Hospital, Hong Kong; 5Medical Unit A, Queen Elizabeth Hospital, Kowloon, Hong Kong;
and 6Department ofMorbid Anatomy, Prince of Wales Hospital, New Territories, Hong Kong.
Summary In a prospective trial of 75 Chinese patients with histologically proven inoperable hepatocellular
carcinoma (HCC), 25 patients were randomised to receive doxorubicin 60-75 mgm2 intravenously once
every 3 weeks, 25 to receive recombinant M2 interferon (rIFN) (Roferon) 9-18 x 106 IU m-2 intramuscularly
(i.m.) daily and 25 to receive rIFN 25-50 x 106 IU m-2 i.m. three times weekly. Patients were switched to the
other drug if: (a) there was progressive disease after 12 weeks, (b) unacceptable toxicity developed and (c) they
had received a total of 500 mg m2 of doxorubicin. Six patients had switching over of therapy, three on
doxorubicin and three on rIFN. In the remaining 69 patients on single drug therapy, the median survival rate
of patients on doxorubicin and rIFN was 4.8 and 8.3 weeks respectively (P = ns.). rIFN induced tumour
regression of 25-50% in 12% of patients and of over 50% in 10% of patients. When compared with
doxorubicin, rIFN was associated with more tumour regression (P = 0.00199) and less progressive tumours
(P= 0.00017). It caused less prolonged and less severe marrow suppression (P= 0.01217), and had
significantly less fatal complications than doxorubicin (P = 0.01383). Doxorubicin caused fatal complications
due to cardiotoxicity and neutropenia in 25% of patients. rIFN was associated with fatal complications due to
dementia and renal failure in 3.8% of patients. In the treatment of inoperable HCC, rIFN is superior to
doxorubicin in causing more tumour regression, less serious marrow suppression and less fatal complications.
Hepatocellular carcinoma (HCC) is one of the 10 commonest
cancers in the world (WHO, 1983), probably the commonest
cancer affecting males, with an estimated annual incidence of
1,000,000 cases (Biscaegli et al., 1988; London, 1981). The
majority (over 95%) of those who present are not operable
(Lai et al., 1981).
Doxorubicin (adriamycin) is the only therapeutic agent
generally accepted to be of some use in its treatment (Olweny
et al., 1980; Chlebowski et al., 1984). Unfortunately, in the
only prospective randomised trial of doxorubicin versus no
antitumour therapy in HCC, it was shown that though dox-
orubicin prolonged the median survival of 3 weeks, it was
associated with fatal toxicity in 25% of patients (Lai et al.,
1988). In that study, we also pointed out that decreasing the
dose of adriamycin would only decrease the chance of
tumour shrinkage in any potential responders. Although
adriamycin was not an ideal drug for the treatment of HCC,
so far no good alternative agent has been described.
Human lymphoblastoid interferon (IFN) was reported to
inhibit the 3H-thymidine uptake by PLC/PRF/5 cell line in a
dose-dependent manner (Dunk et al., 1986). This study also
showed slowing in tumour growth in athymic mice treated
with IFN. For human HCC, two studies had been published
using M2 IFN, one with five patients (four Asians) (Nair et
al., 1985) and one with 16 South Africans (Sachs et al.,
1985). No regression was reported. The number of patients in
both studies was small. There were also no comparison
groups.
The aim of the present study is to compare the effect of
IFN and doxorubicin in the survival, tumour regression and
drug toxicity in 75 Chinese HCC patients.
Materials and methods
Patient selection
Seventy-five consecutive Chinese subjects with histologically
proven HCC who fulfilled the following criteria were
included in the study. (a) Their age were under 75 years old.
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(b) Their tumours were inoperable as assessed by ultrasono-
graphy, CT scan and/or hepatic arteriography (HAG). (c)
They had received no previous surgical resection or
antitumour therapy of any kind. (d) Their Karnovsky scale
was over 70%, i.e. the patient had to be ambulant and able
to take care of most of his own daily needs. (e) Their
bilirubin levels should not be over 50 gLmol 1' (normal<
30gsmol I`). This criterion was chosen because a previous
study of 211 Chinese HCC patients showed that a raised
bilirubin was associated with rapid death (Lai et al., 1981);
this was further confirmed by our study using doxorubicin
(Lai et al., 1988). (f) Their white cell and platelet counts were
over 3 x 109l ' and 75 x 1091' respectively. Their pro-
thrombin time should not be more than 2 s above normal. (g)
They had no basic cardiac disease, clinically, by electrocar-
diography (ECG) and by two-dimensional (2D) echocar-
diogram. (h) Their creatinine levels were not over
0.2 mmol 1' (normal< 0.1 mmol 1-'). (i) A written informed
consent was obtained.
The protocol
All eligible patients were randomised to receive either dox-
orubicin or recombinant a2 interferon (rIFN) (Roferon,
kindly supplied by Hoffmann La Roche, Basle, Switzerland)
on the day of histological confirmation of the diagnosis.
Twenty-five patients received doxorubicin and the other 50
patients were further randomised to receive one of two
regimes of rIFN.
Patients were given doxorubicin in the hospital, starting
with an initial dose of 60 mg m-2 intravenously. If this dose
was well tolerated, they would be given subsequent doses of
75mgm2 intravenously at 3-weekly intervals. Before each
dose of doxorubicin, and at any time the patient complained
of any cardiac symptoms, ECG and 2D echocardiogram were
done. The dose of doxorubicin was reduced by one-third or
one-half if the patient developed severe side-effects
(specifically neutropenia) and if the bilirubin level was, or
started to rise, above the upper limit of normal. The dose of
doxorubicin would be omitted if the white cell count did not
return to 3 x 1091' within 3 weeks. Doxorubicin would be
terminated if cardiotoxicity developed or if the patient had
received a total dose of 500mgm2 (see below).
Patients treated with rIFN were randomised to receive
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either 18 x 106IU m2 intramuscularly (i.m.) daily or
50 x 106IU m2 (i.m.) three times weekly. The first 10
patients received the full dosage of rIFN at the start of
therapy. Since this was found to give rise to fairly frequent
transient decrease in white cell and/or platelet count requir-
ing transient reduction of dosage, the subsequent patients
were started on two doses of 9 x 106 IU m-2 IMI daily or
25 x 106 IU m-2 i.m. thrice weekly. The dose was escalated
through two doses of 15 x 106IUm2 or 35 x 106 IU m2
respectively to the full dose by the fifth dose. Patients whose
conditions were not deteriorating were discharged and
treated on an outpatient basis until their terminal stage. The
dosage of rIFN was reduced by one-third (or very
occasionally by one-half or one-quarter) if the patients
developed neutropenia of below 2 x 1091', throm-
bocytopenia of below 30 x 1091-' or severe fatique. If the
cell counts returned to normal, they were put back on the
full dose. rIFN was stopped if any severe untowards events
developed, irrespective of whether the events were deemed to
be related to rIFN or not.
All patients were seen weekly at an outpatient clinic for
clinical assessment of their liver size, their complete blood
picture, liver and renal laboratory tests, serum alpha feto-
protein (AFP), serum ferritin and urine examination. Side-
effects were carefully recorded. Chest X-rays were taken
every 4 weeks. The tumour size was assessed by ultrasono-
graphy at 4-weekly intervals and by CT scan and/or HAG at
12-weekly intervals.
Patients on doxorubicin were switched over to rIFN i.m.
three times weekly, and those on rIFN to adriamycin if there
was progressing tumour after 12 weeks of initiation of
therapy or if unacceptable toxicity due to the drug treatment
developed. Patients receiving doxorubicin were also switched
over to rIFN i.m. thrice weekly if they had received a total
dose of 500mgm-2
This protocol was approved by the Ethical Committee of
the University of Hong Kong, Queen Mary Hospital, Hong
Kong. (The Ethical Committee thought it was unethical to
have a control limb with no antitumour therapy.)
Criteriafor tumour regression
In patients surviving over 4 weeks, tumour regression was
defined as at least 25% reduction in three of the following
four criteria: (1) the product of the maximum diameter of the
tumour and the diameter perpendicular to this in the sagittal
plane; (2) the sum of the liver span as measured at the right
(and the left if palpable) mid-clavicular line and at the
xiphisternum; (3) serum AFP and/or ferritin levels; and (4)
tumour size at diagnosis and at autopsy in the sagittal plane.
There must also be no evidence of new or progressive meta-
stases, especially on chest X-ray.
Table I shows the demographic data of the 75 patients
before the institution of treatment. There were no differences
in any of the parameters in all three groups. Nineteen sub-
jects presenting during the period of the study were excluded,
12 of these because of bilirubin levels of above 50 ,mol
on presentation.
Statistical analyses were done using x2 test, Fisher's exact
test, Student's t test, Mann-Whitney test and actuarial sur-
vival by SPSS (SPSS Inc., Chicago, IL, USA).
Results
The six patients with switching ofdrug therapy
Three patients receiving doxorubicin had stable tumour until
they received up to 495-505 mgm2 of doxorubicin. They
were then switched over to r-IFN three times weekly. All
three patients, aged 26, 28 and 56 years, died of intractable
cardiac failure because of cardiomyopathy 1 week, 12 weeks
and 8 months respectively after switching over to rIFN. The
patients who survived for 12 weeks and 8 months had
25-50% and over 50% shrinkage of tumours respectively,
both starting within 4 weeks of receiving rIFN.
Three patients receiving rIFN, one on the daily regime and
two on the three times weekly regime, were switched over to
doxorubicin at week 12 because of progressive disease. All
continued to have progressive disease while on doxorubicin.
Two died of progressive tumours at weeks 4 and 12 after
switching over to doxorubicin. One patient, aged 37 years
died of cardiomyopathy 29 weeks after switching over and
receiving 505 mg m-2 of doxorubicin.
The 69 patients on single drug therapy
The two groups receiving rIFN will be grouped together
from this point onwards (except when specifically men-
tioned), as there were no significant differences in patient
survival, tumour shrinkage or side-effects between the two
regimes of rIFN.
Survival
The actuarial survival of the 22 patients receiving dox-
orubicin alone and of the 47 receiving rIFN alone is shown
in Figure 1. The median survival for the doxorubicin group
was 4.8 weeks and for the rIFN group was 8.3 weeks. For
those receiving doxorubicin alone, nine patients received one
course only, five received two courses, and the rest received
from three to seven courses. There was no statistical
difference between the two curves although there was a
slightly higher proportion of patients surviving for over 12
weeks in the rIFN group (38.3%) than in the doxorubicin
group (31.8%).
Tumour regression
Sixteen patients receiving doxorubicin alone and 36 patients
receiving rIFN alone survived for over 4 weeks, and were
Table I Demographicdataof75 patientswith inoperable hepatocellular carcinoma randomized to receive
doxorubicin or recombinant x2 interferon (rIFN)
rIFN
rIFN (three times
Doxorubicin (daily) weekly)
Number of patients 25 25 25
Male:female 21:4 22:3 24:1
Median age in years (range) 52 48 56
(28-73) (38-69) (37-67)
Mean Karnovsky status (%) 90 90 90
Mean time from admission to randomisation
in weeks 3 3 3
Per cent positive for HBsAg 88 88 88
Per cent positive for HBeAg 27 33 29
Per cent positive for anti-HBe 63 53 57
Median bilirubin (jtmol 1-) 24 23 23
(normal range 4-30) (4-50) (6-50) (5-50)
Per cent with AFP over 200 ng ml-' 70 73 67
Median AFP level (ng ml-') 3200 2269 2820
(2-83,000,000) (14-971,000) (3-2,268,200)UU
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Figure I The survival curves of 22 patients on adriamycin alone (continuous line) versus 67 patients on recombinant Y2 interferon
alone (dotted line).
assessable for tumour regression. The status of the tumour
size of these patients is tabulated in Table II. The rIFN
group was associated with a significantly larger proportion of
patients with tumour regression as well as a lesser proportion
with progressing tumours. Even when the six patients with
switching of drug therapy were included in the analysis (i.e.
three more patients on initial doxorubicin with stable
tumours and three on initial rIFN with progressing tumours),
rIFN was still associated with a smaller proportion of pro-
gressing tumours (x2 = 5.431, P<0.025).
rIFN-induced tumour progression was usually clinically
apparent within 2-3 weeks of institution of therapy. (Two
patients dying at 2.5 weeks of renal failure and of
haemoperitoneum had 25% and over 50% of tumour regres-
sion before death; they were excluded from analysis because
of their early deaths.) Of the 11 patients on rIFN surviving
over 4 weeks with tumour regression, five had over 50%
regression and six had between 25-50% regression (i.e. 10%
and 12% respectively out of 50 patients randomised to
Table II Status ofthe tumour size in 52 patients with HCC receiving
doxorubicin or rIFN
rIFN
Three times
Doxorubicin Daily weekly TotaP P
Progressing 13 6 5 11 0.00017
Stable 3 10 4 14 n.s.
Regressing 0 4 7 11 0.00199
aThe total number ofpatients onrIFN was used foranalysis (Fisher's
exact test).
receive rIFN). Figure 2 shows (a) the initial HAG of a
patient, aged 67, with over 75% tumour regression, and (b)
his CT scan at week 16 when the tumour was only 3 cm in
diameter and no longer visualised by HAG. Figure 3 shows
his tumour of 3 cm in diameter at autopsy when he died of
dementia at 110 weeks after treatment. The other four
patients with over 50% tumour regression survived for 12.5,
40, 40 and 70 weeks.
In this study, none of the doxorubicin patients qualified
for tumour regression. (One patient had around 15% tumour
regression with the first two doses of doxorubicin but
thereafter had slowly progressive tumour.)
Figure 3 The tumour of the same patient as in Figure 2 at
autopsy 110 weeks after initiation of interferon therapy.
Figure 2 The left side shows the hepatic arteriogram of a 67-year-old patient with massive hepatocellular carcinoma. The right
side shows the same patient with tumour of 3 cm diameter detected only by CT scan 16 weeks after initiation of interferon therapy.
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Causes ofdeath
The causes of death are tabulated in Table III. There was a
higher incidence of rupture of tumour in the rIFN group
(17%) than in the doxorubicin group (0%). All eight patients
with tumour rupture had autopsies. There was no evidence of
tumour lysis, with six patients showing progressive tumours.
The incidence of tumour rupture in rIFN-treated patients
was not different from those receiving no treatment in a
previous study (Lai et al., 1981). The three patients on
doxorubicin dying of septicaemia will be discussed below.
Side-effects andfatal complications ofdrug therapy
A total of 28 patients were put on doxorubicin and 53
patients on rIFN. Their side-effects are listed in Table IV.
The patient of rIFN with wheezing attack developed it 9 h
after the first dose; the patient with mental confusion
developed it 12 h after the first dose. Both patients had no
recurrence of the symptoms on being given the second dose.
Fatigue was difficult to assess in HCC patients. In only two
patients receiving rIFN was a permanent reduction in dosage
by one-half required because of fatigue.
The marrow suppression was defined as severe if the white
cell count dropped to below 1 x 1091'. In the doxorubicin
group, the maximum drop in white cell and/or platelet count
was usually 10-14 days after the injection. The counts only
returned to normal after 7-10 days. The degree of neut-
ropenia was not predictable by the patient's previous res-
ponse to the same dosage. Three patients died of septicaemia
during a neutropenic episode in spite of intensive antibiotics
therapy; while three others required permanent reduction to
half or one-quarter of the dosage of doxorubicin. rIFN-
induced marrow suppression usually occurred within 2-4
days of initiation of treatment, the cell counts returning to
pre-treatment levels in another 2-4 days after cessation of
rIFN. Gradual escalation of the dosage of rIFN reduced the
occurrence as well as the recurrence of marrow suppression
(see Protocol above). Only three patients required permanent
reduction to one-half or one-quarter of their rIFN dosage;
the others were slowly escalated to the full dose without
further significant marrow suppression. There was a
Table III Causes ofdeath in69 HCC patients oneitherdoxorubicin or
rIFN alone
Doxorubicin rIFN
Number of patients 22 47
Causes of death (%)
Tumour progression 86.4 72.3
Rupture of tumour 0 17.0
Variceal bleeding 0 6.4
Septicaemia due to neutropenia 13.6 0
Renal failure 0 2.1
Dementia 0 2.1
P = n.s. (Fisher's exact test)
Table IV Side-effects of doxorubicin and rIFN in the treatment of
HCC
rIFN
Three times
Doxorubicin Daily weekly Total
Number of patients 28 25 28 53
'Flu' syndromea 0 25 28 53
Wheezinga 0 1 0 1
Mental confusiona 0 0 1 1
Nausea ± vomiting 28 0 0 0
Fatigue 11 4 3 7
Marrow suppression
moderate 6 5 6 11
severe 6 1 0 1
Cardiotoxicity 4 0 0 0
Renal impairment 2 0 1 1
Dementia 0 1 0 1
aSide-effects with rapid tachyphylaxis.
significantly higher proportion of patients on doxorubicin
with severe marrow suppression (21.4%) than those on rIFN
(1.9%) (P = 0.01217 by Fisher exact test).
All four patients who developed cardiomyopathy with dox-
orubicin died. Only one patient was over the age of 50. He
died 8 months after having been switched over to rIFN (see
below). None of them had symptoms, signs or echocardio-
graphic evidence of cardiac diseases on cessation of dox-
orubicin. In all four patients the cardiomyopathy occurred
suddenly, causing death within 24-48 h.
The two patients on doxorubicin who developed renal
failure did so during the terminal stage of liver failure. The
one patient on rIFN who developed renal failure was aged 64
years and had hyperuricaemia and a slightly raised serum
creatinine of 0.15 jLmol 1' before treatment. After two doses
of rIFN, he developed hyperkalaemia of 6.9 mmol 1-'. There
was no evidence of tumour lysis. The rIFN was stopped. His
renal function deteriorated in spite of lowering of the serum
potassium. He died 2.5 weeks after initiation of rIFN.
The patient on rIFN who had dementia was the 67-year-
old man who had rIFN for 110 weeks and over 75% tumour
regression. He developed increasing irritability and later
urinary incontinence at week 95. CT scan of the brain
showed mild cerebral atrophy. rIFN was stopped at week
105. He died at the age of 69, his tumour remaining at 3 cm
at death (Figure 3). He was negative for antibodies against
the human immunodeficiency virus (HIV).
Table V shows the fatal complication associated with dox-
orubicin and rIFN. The causal relationship between the
deaths due to renal failure and dementia with rIFN are not
certain (see Discussion).
Discussion
The present trial was designed to study the effect of rIFN, in
HCC. rIFN is reported to be of use in vitro (Dunk et al.,
1986), but was of no use in two uncontrolled trials in human
HCC (Nair et al., 1985; Sach et al., 1985). It is therefore
essential to compare its effect with a standard agent for the
treatment of HCC. Doxorubicin was chosen as it was the
only agent generally accepted to be of some use. However,
with the re-confirmation of the fatal side-effects of dox-
orubicin in this present study to be identical to our previous
trial (Lai et al., 1988), it would be preferable to compare
rIFN treated patients with patients on no treatment.
Patient survival
There was no statistical difference in the survival curves of
patients on doxorubicin and on rIFN (Figure 1). For those
on rIFN, there was an improvement in the median survival
rate from 4.8 to 8.3 weeks as well as a slight increase in the
proportion surviving over 12 weeks. The poor median sur-
vival for both groups of patients, even after exclusion of
patients with raised bilirubin levels from this trial,
reconfirmed that our HCC patients presented late (Lai et al.,
1981, 1988). In the former study (Lai et al., 1981), the
median survival of 104 unselected patients with HCC was 3.5
weeks. However, patients with tumour regression (on rIFN)
did show a tendency for longer survival. Unfortunately, there
were no criteria by which to predict which patient would
Tabje V Fatal complications due to doxorubicin or rIFN in HCC
patients
Doxorubicin rIFN
Total number of patients 28 53
Fatal complications
Cardiotoxicity 4 0
Septicaemia 3 0
Renal failure 0 1
Dementia 0 1
Per cent of deaths 25 3.8
P = 0.01383 (Fisher's exact test).932 C.-L. LAI et al.
respond, and which would die early and therefore not benefit
from treatment of any kind, even given the fairly stringent
criteria by which we included patients for the trial. There are
three different approaches to this difficult dilemma of treating
HCC patients more profitably with less patient discomfort
and longer survival.
Firstly, since all 11 of our responders to rIFN showed
tumour shrinkage within the first 4 weeks of treatment, it
may be advisable to give all eligible patients a 4-8 week trial
period in any future trials with rIFN. Those showing no
response within 4-8 weeks may then be withdrawn from
rIFN for the benefit of the patients. Since the two regimes of
rIFN gave similar results, the three times weekly regime is to
be recommended for patient convenience. Secondly, it is
possible that the dose of rIFN can be reduced to decrease
uncomfortable side-effects, mainly fatigue. The large doses of
rIFN chosen in both regimes in this trial were justified by the
in vitro finding that decrease in 3H-thymidine uptake by
PLC/PRF/5 cells was dose-dependent (Dunk et al., 1986).
This is further confirmed by the ineffectiveness of the two
previous trials in human HCC using lower dosages of IFN
(Nair et al., 1985; Sacs et al., 1985). Determination of the
optimal dosage of rIFN for inducing tumour regression in
human HCC will require a study on a much larger scale than
the present trial.
A third, completely different, approach to improving patient
survival is to detect subclinical HCC (SCHCC) by routine AFP
and ultrasound screening of high risk subjects, specifically
hepatitis B carriers. However, the local experience with AFP
screening was disappointing (Lok & Lai, 1989). Very few
SCHCC were detected. They were often multicentric and/or in
surgically inaccessible site, superimposed on grossly cirrhotic
livers. In Shanghai, although the routine survey of AFP
increased the number ofSCHCC among HCC patients from 0%
in 1961-1970 to 17.7% in 1970-1982 (Tang, 1985), it must be
stressed that even in the later period, the actual number of
clinical HCC versus SCHCC patients was 466 to 100. The
overall resectability rate of 30.9% in the 566 patients was
therefore only slightly better than the 24.7% in those with
clinical HCC (y2 = 4.622, P<0.05).
Thus, inoperable HCC presenting late will probably remain a
major cancer problem in spite of vigorous application of early
detection methods. Until the possible decrease in incidence of
HCC with the widespread vaccination of infants with the
hepatitis B vaccine (Lai, 1985), rIFN is a superior agent to
doxorubicin for HCC (see below), even if its prolongation of
patient survival is limited.
Tumour regression
Compared with doxorubicin, there was significantly more
tumour regression and less tumour progression in the rIFN
groups in this trial. rIFN induced tumour regression in 22%
of our patients, with 10% having over 50% regression as
required by the WHO standard. (If we include the three
patients switched over from doxorubicin to rIFN, then
24.5% of patients had tumour regression, with 11.3% having
over 50% regression.) The lack of regression in the two
studies published using IFN in HCC may be due to the
smaller size of patient samples and/or the lower dosages used
in both studies (Nair et al., 1985; Sachs et al., 1985).
The complete lack of tumour regression in all 28 patients
receiving doxorubicin in this study may be due to the com-
paratively small sample of patients. However, even in a
previous study of doxorubicin with 60 patients, only 8.3%
had tumour regression with 3.3% having over 50% regres-
sion (Lai et al., 1988). These figures are still much lower than
those for rIFN in this study.
Side-effects andfatal complications ofdoxorubicin and rIFN
The high fatal complication rate of 25% of patients treated
with doxorubicin in this trial is identical to that in a previous
study (Lai et al., 1988). In both trials, the causes of death
were neutropenia and cardiotoxicity. The degree of neut-
ropenia was unpredictable from the previous courses of dox-
orubicin and therefore unpreventable. This also applied for
the cardiotoxicity. Because of the 'escape' route of switching
of drug therapy in this trial, none of the four patients dying
of cardiotoxicity received more than the usually accepted
'non-cardiotoxic' dose of 500 mg m2. In spite of this, all
eventually died of cardiomyopathy. Even for the 56-year-old
patient who died of cardiac failure due to cardiomyopathy 8
months after switching over to rIFN, doxorubicin was still
the most likely causal agent because (a) the patient's 2D
echocardiogram showed the typical ventricular hypocontrac-
tility of doxorubicin-induced cardiomyopathy, (b) his ECG
revealed no evidence of myocardial ischaemia and (c) it is
well documented that doxorubicin-induced cardiomyopathy
may occur as long as 12 months after cessation of therapy
(Henderson & Frei, 1980). This high fatality rate due to
cardiotoxicity (4%) in spite of a 'non-cardiotoxic' dose is not
observed in the Caucasian population. This may be due to
the high dosages of doxorubicin that were used in our study,
even though the dosages were the standard dosages recom-
mended for HCC and even though we have tailored the
dosages for patients with bilirubin levels above normal (see
'Protocol' above). A possible alternative explanation is the
differences in racial susceptibility to doxorubicin. We would
like to emphasise that doxorubicin should be used with ext-
reme caution, especially in the presence of impaired hepatic
functions.
In the rIFN group, the tolerance of the drug was good in
most cases. This differs from the finding of Sachs et al. (1985)
where seven out of 16 patients tolerated the drug badly. In
our study, one patient had a wheezing attack and one had
mental confusion with the first dose only. The degree of
marrow suppression was less severe (P = 0.01217) and more
transient than doxorubicin, most likely because rIFN is
cytostatic whereas doxorubicin is cytocidal. Seven patients
(13.2%) on rIFN had significant fatigue, with two requiring
permanent reduction of dosage. This compares favourably
with the 39.3% of the doxorubicin group who also had
significant fatigue lasting 2-7 days after each injection.
Mental confusion and fatigue are well documented neuro-
psychiatric complications with rIFN treatment (Adams et al.,
1984; McDonald et al., 1987). However, no organic changes
or damages had been reported to date. In the present trial,
one patient died at age 69 years of dementia, with CT scan
showing mild cerebral atrophy. It is uncertain whether rIFN
had any causal relationship with his dementia. His age and
the demonstrable cortical atrophy as well as the absence of
antibody against HIV are against rIFN as a causal factor.
On the other hand, he had received a daily dose of
18 x 106 IU m 2 of rIFN for 105 weeks. The absolute possi-
bility of organic cerebral damage with such a prolonged large
dose of rIFN could not be ruled out.
The casual relationship of rIFN with the other death due
to renal failure following hyperkalaemia is also uncertain.
rIFN can cause transient reversible renal failure. Our patient
had hyperuricaemia and a mildly elevated serum creatinine
before initiation of rIFN. The episode of hyperkalaemia
following two doses of rIFN could not be due to tumour
lysis as there was no evidence of tumour regression. It was
this episode of hyperkalaemia that triggered off the fatal
renal failure even though rIFN was stopped promptly.
Thus, the relationship between the rIFN treatment and
both deaths in this group remains uncertain. But even assum-
ing that there was a direct causal relationship, rIFN caused
death in only 3.8% of patients, much lower than the un-
acceptable 25% associated with doxorubicin therapy
(P = 0.01383).
In conclusion, in the treatment of inoperable HCC in
patients with relatively good Karnovsky scale and hepatic
function, rIFN when compared with doxorubicin gave rise to
slightly but not significantly better patient survival. It was
associated with a significantly lower proportion of progres-
sive tumour and a higher proportion of regressing tumour
(12% between and 25-50% regression, and 10% over 50%
regression). It was also a much safer drug. Most of itsINTERFERON AND DOXORUBICIN IN HEPATOMA 933
side-effects either showed tachyphylaxis or were mild and
transient. It was associated with a much lower fatal comp-
lication rate than the 25% due to doxorubicin. Further trials
of rIFN in inoperable HCC should be carried out to substan-
tiate our findings as well as to determine the optimal dose.
We are conducting a second trial comparing rIFN with no
treatment in HCC patients.
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